Terminated PHASE3 INTERVENTIONAL 1-arm NCT01785771

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c

Sponsor: Intarcia Therapeutics

Conditions Type 2 Diabetes

Interventions ITCA 650 (exenatide in DUROS)

Updated 10 times since 2017 Last updated: Mar 4, 2019 Started: May 31, 2013 Primary completion: Jan 31, 2018 Completion: Jan 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Decision by Sponsor

Other terminated trials from Intarcia Therapeutics

See all terminations from Intarcia Therapeutics

Other Type 2 Diabetes trials with similar outcome

Browse all Type 2 Diabetes trials

This PHASE3 trial investigates Type 2 Diabetes and is currently terminated or withdrawn. Intarcia Therapeutics leads this study, which shows 10 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE3
Apr 2019 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 5 earlier versions

Jun 2018 — Apr 2019 [monthly]

Terminated PHASE3
Feb 2018 — Jun 2018 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Jul 2017 — Feb 2018 [monthly]

Active Not Recruiting PHASE3
Feb 2017 — Jul 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Intarcia Therapeutics

Data source: Intarcia Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Austin, United States , Avon, United States , Birmingham, United States , Bradenton, United States , Chandler, United States , Charlotte, United States , Chicago, United States , Chula Vista, United States , Cincinnati, United States and 36 more locations